After the Human Research Ethics Committee (HREC) rejected the Company’s flagship drug, EmtinB, knocking back years of research in the process, disappointed CEO and Managing Director, Mr Matt Liddelow, announced that he is resigning from his position immediately. Liddelow noted, “I acknowledge the loss in shareholder value as a result of the rejected Human Research
Read More
Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase 2 study of their flagship drug, pentosan polysulfate sodium (PPS) in patients with Mucopolysaccharidosis type VI (MPS VI). A big word to digest on a Friday morning, I know. The inherited disease is caused by
Read More
Clinical data trials being conducted by Paradigm Biopharmaceuticals (ASX: PAR) continue to deliver impressive patient outcomes for sufferers of chronic joint pain and osteoarthritis with 13 new patients having joined the trials and reported significantly better quality of life upon treatment with Zilosul. The most recent round of trials have been conducted in Australia under
Read More